📌 Insmed ( 
INSM) – Breakout Opportunity
Insmed is a clinical-stage biopharmaceutical company focused on serious and rare lung diseases. The stock more than doubled in May 2024 following positive Phase 3 results for its drug Brensocatib. The FDA has granted Priority Review, with a PDUFA date set for August 12, 2025 — and commercial launch expected in H2 2025.
Technical Overview:
Since the massive gap up in May 2024, INSM has been trading inside a well-defined horizontal channel between:
🔻 Support: $61.65
🔺 Resistance: $84.82
Currently, price is near the upper third of the range (~$79.92), showing signs of renewed momentum with rising volume and RSI trending higher.
Plan
----
📍 Entry: Daily close above $85 with strong volume (>2.5M)
Targets
🎯 Target 1: $94 (+11%)
🎯 Target 2: $106 (+25%)
🛑 Stop: $82 (-4.7%)
Risk ratio:
🟠 Target 1: > 2:1
🟢 Target 2: > 5:1
---
📊 Key Indicators to Watch:
✅ RSI > 60 with upward slope
✅ MACD bullish crossover
✅ Break above 20-day EMA with volume
✅ Volume expansion on green candles
⚠️ This content is for informational and educational purposes only and does not constitute investment advice ⚠️
INSM) – Breakout OpportunityInsmed is a clinical-stage biopharmaceutical company focused on serious and rare lung diseases. The stock more than doubled in May 2024 following positive Phase 3 results for its drug Brensocatib. The FDA has granted Priority Review, with a PDUFA date set for August 12, 2025 — and commercial launch expected in H2 2025.
Technical Overview:
Since the massive gap up in May 2024, INSM has been trading inside a well-defined horizontal channel between:
🔻 Support: $61.65
🔺 Resistance: $84.82
Currently, price is near the upper third of the range (~$79.92), showing signs of renewed momentum with rising volume and RSI trending higher.
Plan
----
📍 Entry: Daily close above $85 with strong volume (>2.5M)
Targets
🎯 Target 1: $94 (+11%)
🎯 Target 2: $106 (+25%)
🛑 Stop: $82 (-4.7%)
Risk ratio:
🟠 Target 1: > 2:1
🟢 Target 2: > 5:1
---
📊 Key Indicators to Watch:
✅ RSI > 60 with upward slope
✅ MACD bullish crossover
✅ Break above 20-day EMA with volume
✅ Volume expansion on green candles
⚠️ This content is for informational and educational purposes only and does not constitute investment advice ⚠️
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.